Standard BioTools Inc (NASDAQ:LAB) price closed lower on Friday, March 22, dropping -0.74% below its previous close.
A look at the daily price movement shows that the last close reads $2.70. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.16 and 52-week low of $1.46. The stock added 14.04% on its value in the past month.
Standard BioTools Inc, which has a market valuation of $777.52 million, is expected to release its quarterly earnings report May 07, 2024 – May 13, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give LAB a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.
The overview shows that LAB’s price is at present 4.52% off the SMA20 and 10.20% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 58.02, with weekly volatility standing at 5.22%. The indicator jumps to 6.41% when calculated based on the past 30 days. Standard BioTools Inc (NASDAQ:LAB)’s beta value is holding at 1.64, while the average true range (ATR) indicator is currently reading 0.15.
An analysis of the Standard BioTools Inc (NASDAQ:LAB) stock in terms of its daily trading volume indicates that the 3-month average is 1.87 million. However, this figure increases on the past 10-day timeline to an average of 1.97 million.
Current records show that the company has 290.12M in outstanding shares. The insiders’ percentage holdings are 3.33% of outstanding shares while the percentage share held by institutions stands at 47.78%. The stats also highlight that short interest as of Feb 29, 2024, stood at 7.92 million shares, which puts the short ratio at the time at 6.16. From this we can glean that short interest is 2.73% of company’s current outstanding shares. Notably, we see that shares short in February rose slightly given the previous month’s figure stood at 7.3 million. But the 21.27% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
